148 results about "Bifidobacterium lactis" patented technology

The present application relates to animal bifidobacterium lactis Ca360 and its application. The present application also provides the application of animal bifidobacterium lactis in promoting the absorption and transport of minerals, improving osteoporosis, iron deficiency anemia and zinc deficiency. The animal bifidobacterium lactis of the present application can promote the absorption and transport of minerals, improve osteoporosis, iron deficiency anemia and zinc deficiency.

The invention provides an application of bifidobacterium animalis subsp. Lactis CP-9 in preparation of a product for promoting bone growth and development or improving bone health. Long-term research and a large number of experiments show that the bifidobacterium animalis subsp. Lactis CP-9 can improve the bone volume fraction, the bone trabecula thickness, the bone density and the bone volume of an organism, and can also effectively improve the growth hormone level and the insulin-like growth factor 1 level, so that bone growth and development are promoted. Meanwhile, the bifidobacterium animalis subsp. Lactis CP-9 can effectively improve the N-terminal propeptide level, osteocalcin level, bone morphogenetic protein level and osteoprotectin level of I-type procollagen in a body, and remarkably reduce the amino-terminal peptide level of the I-type collagen and the ligand level of nuclear factor kappa B receptor activating factor, so that osteoblast differentiation is promoted, osteoclast differentiation is inhibited, and osteoclast differentiation is inhibited. Furthermore, bone formation is promoted, bone resorption is inhibited, bone metabolism is improved, and finally the effect of improving bone health is achieved.

The invention discloses bifidobacterium animalis subsp. Lactis, a preparation and application of the bifidobacterium animalis subsp. Lactis in regulation of depression and intestinal flora. Belongs to the technical field of probiotic preparation. According to the application, seven strains of bacteria are separated from excrement of infants, the seven strains of bacteria comprise bifidobacterium breve, bifidobacterium animalis and bifidobacterium longum through identification, the anti-depression capacity of the seven strains of bacteria is evaluated through in-vitro experiments, a potential antidepressant bifidobacterium animalis subsp. Lactis BD1 is screened out, and further experiments prove that the antidepressant bifidobacterium animalis subsp. Lactis BD1 has the advantages that the antidepressant bifidobacterium animalis subsp. Lactis BD1 can be used for preparing the antidepressant bifidobacterium animalis subsp. Lactis BD1; the strain has the effects of improving depressive mood, intestinal bacteria unbalance and insufficient serotonin secretion in the brain caused by chronic bound stress (CRS), and compared with bifidobacterium animalis subsp. Lactis in the prior art, the strain achieves the anti-depression effect from multiple aspects, also has the effect of adjusting intestinal flora imbalance, and has the advantages of being safe and reliable. And a new treatment strategy is provided for depression and intestinal flora imbalance.

The invention relates to a bifidobacterium animalis subsp. Lactis B7 as well as a composition and application thereof, and belongs to the technical field of microorganisms, the bifidobacterium animalis subsp. Lactis B7 is preserved in the China Center for Type Culture Collection on April 19, 2024, and the preservation number is CCTCC NO: M2024734. The bifidobacterium animalis subsp. Lactis B7 is named as Bifidobacterium animalis subsp. Lactis B7, the composition is named as Bifidobacterium animalis subsp. Lactis B7, and the composition is named as Bifidobacterium animalis subsp. Lactis B7. The invention also discloses application of the B7 fermentation composition in preparation of medicines for preventing and treating ulcerative colitis, constipation and constipation-type ulcerative colitis. According to the bifidobacterium animalis subsp. Lactis B7, high-yield short-chain fatty acid and indolepropionic acid are achieved, sulforaphane is generated through glucoraphanin, intestinal tract movement is improved, ulcerative colitis or inflammatory bowel disease activity index DAI and weight loss caused by the disease activity index DAI are effectively relieved, mouse colon injury is remarkably relieved, and mucosa layers are protected; the effects of resisting inflammation, inhibiting pathogenic bacteria and improving the intestinal barrier function are achieved.

The invention discloses bifidobacterium animalis and application thereof in allergic rhinitis products, and belongs to the technical field of microorganisms. The technical problem to be solved is that the existing common allergic rhinitis treatment means cannot meet the requirements of patients on safety, long-acting effect and treatment cycle. The invention provides an animal bifidobacterium subsp. Lactis Def +, and after an effective dose of animal bifidobacterium subsp. Lactis Def + is applied to a subject, the animal bifidobacterium subsp. Lactis Def + is found to be capable of remarkably relieving the allergic rhinitis symptom. Specifically, the symptoms of sneezing, dry nose and rhinocnesmus are reduced; the number of nasal septum mucosa intrinsic layer inflammation infiltration cells and nasal septum mucosa epithelium pathological changes are reduced; the IgA and IgE levels of serum are reduced; the levels of proinflammatory factors IL-4, IL-5 and IL-13 are reduced; the normal spleen index is maintained; the imbalance state of Th1 / Th2 and Th17 / Treg is effectively improved, and the body immunity is improved; a safe and long-acting scheme is provided for allergic rhinitis diseases.

The invention discloses a primer composition and application of the primer composition in detection of animal bifidobacterium subsp. Lactis HN019. According to the present invention, bifidobacterium animalis subsp. Lactis HN019 is adopted as an object, bacterial strain specific genetic markers are screened through whole genome sequencing and single nucleotide polymorphism analysis, and a fluorescent quantitative PCR technology is combined so as to obtain the efficient, specific and stable HN019 quantitative detection primer composition and the method thereof; through system verification, the method is suitable for an HN019 strain level detection technical framework in scientific research and industrial application scenes, and also provides key technical support for market supervision and industrial healthy development of probiotic foods.

The invention discloses a panax quinquefolius probiotic beverage and a preparation method thereof, and relates to the technical field of functional foods. According to the beverage, the combination of the American ginseng extract and specific probiotics is taken as a core, the survival rate of thalli is increased by adopting a microcapsule embedding technology, and the product performance is optimized by adding a stabilizer and a flavor regulator. The formula comprises 5-15% of a panax quinquefolius extract, 3-8% of compound probiotic freeze-dried powder (lactobacillus plantarum, lactobacillus salivarius and bifidobacterium lactis), 10-25% of inulin, 5-15% of whey protein, 10-30% of a microcapsule wall material (sodium alginate / chitosan or a WPI-KGM compound), and auxiliary materials. According to the preparation method, the active ingredients are efficiently reserved through the processes of gradient extraction, microcapsule embedding, low-temperature drying and the like. The product has the functions of resisting fatigue, regulating intestinal flora and enhancing immunity, the survival rate of probiotics in simulated gastric juice reaches 85% or above, and the shelf life stability is improved by 40%.

The invention discloses a synbiotics composition with bacteriostatic and anti-inflammatory effects, which comprises probiotics and prebiotics in parts by weight, the probiotics comprise the following components in parts by weight: 0.05 to 0.15 part of freeze-dried powder of lactobacillus rhamnosus PB-LR76, 0.05 to 0.15 part of freeze-dried powder of lactobacillus acidophilus HH-LA26, 0.05 to 0.15 part of freeze-dried powder of lactobacillus bulgaricus HH-LB57, 0.05 to 0.15 part of freeze-dried powder of bifidobacterium lactis HH-BA68, 0.05 to 0.15 part of freeze-dried powder of lactobacillus reuteri PB-LR09, and 0.05 to 0.15 part of freeze-dried powder of lactobacillus plantarum HH-LP56; the prebiotics are fructo-oligosaccharide or a rhizoma polygonati extract. Compared with the single use of probiotics or prebiotics, the synbiotics composition disclosed by the invention has stronger antibacterial and anti-inflammatory effects. The invention further discloses application of the synbiotics composition in preparation of a medicine for treating enteritis.

The invention discloses a compound probiotic for improving cognitive function of old people and a preparation method and application thereof. Firstly, maltodextrin is dried and then sieved, metal impurities are removed after sieving, and maltodextrin freeze-dried powder, lactobacillus paracasei Lpc37 freeze-dried powder, phytobacterium plantarum Lp-115 freeze-dried powder and bifidobacterium animalis subsp. Lactis Bl-04 freeze-dried powder are weighed and sieved respectively; the preparation method comprises the following steps: preparing freeze-dried powder of three strains, then premixing the freeze-dried powder of the three strains with a part of maltodextrin, adding the residual maltodextrin after the strains are premixed, continuously mixing until the materials are uniformly distributed to obtain the compound probiotics, exerting a synergistic effect through a specific strain combination (Lp115 + Lpc37 + Bl-04), providing a new way for non-drug intervention, being beneficial to regulating intestinal flora metabolism (such as generating short-chain fatty acid SCFA), and improving the immunity of the human body. The synthesis and release of neurotrophic factors are promoted, the nerve cell function is improved, and the cognitive function improvement is indirectly assisted.

The invention discloses bifidobacterium animalis subsp. Lactis and application thereof in a product for enhancing athletic ability, and relates to the technical field of microorganisms. The invention provides an animal bifidobacterium subsp. Lactis MUS < + >, and the preservation number of the animal bifidobacterium subsp. Lactis MUS < + > is CGMCC (China General Microbiological Culture Collection Center) No.35626. The invention also provides a preparation method of the animal bifidobacterium subsp. Lactis MUS < + >. The animal bifidobacterium subsp. Lactis MUS + provided by the invention can increase the length of surrounding motor nerves and promote the development of the motor nerves; the total exercise distance is increased, and the exercise ability and endurance are promoted; body length or height development is promoted; muscle fibers are thickened, the muscle fiber density is increased, muscle fiber gaps are reduced, and muscle development is promoted; and the method has a very good application prospect in preparation of products for improving athletic ability or increasing muscle.

The invention discloses application of animal bifidobacterium subsp. Lactis GOLDGUT-BB21 in preparation of products for relieving depression, and belongs to the technical field of biological medicine. The probiotics disclosed by the invention can be used for relieving depressive symptoms, improving related symptoms, assisting in treating depression and preventing depression, and also can be used as a nutritional supplement to help maintain the balance of intestinal microflora and promote intestinal health.

The invention relates to the technical field of dairy product fermentation, and discloses a high-activity probiotic microcapsule suitable for dairy product fermentation and a preparation method thereof.The microcapsule is prepared from, by weight, 6.7-13.3 parts of bifidobacterium lactis, 3.3-6.7 parts of lactobacillus plantarum, 9.1-15.2 parts of Arabic gum, 13.6-22.7 parts of maltodextrin, 7.3-12.1 parts of chitosan, 15.1-30.2 parts of trehalose, 3.8-7.5 parts of glycerinum and 1.1-2.3 parts of ascorbic acid. The molecular weight of the chitosan is 80kDa, and the weight part ratio of the bifidobacterium lactis to the lactobacillus plantarum is 2: 1. In the invention, an inner core is formed through a eutectic structure of bifidobacterium lactis, lactobacillus plantarum and trehalose to protect the probiotics, so that the problems that the existing probiotics are easily influenced by the external environment in the storage and fermentation processes, the activity is reduced, and the fermentation effect of dairy products is poor are solved.

The invention relates to a polygonatum sibiricum probiotic compound preparation with an aging delaying effect and application thereof. The compound preparation comprises a polygonatum sibiricum extract and a probiotic composition, the bacterial strains in the probiotic composition comprise a combination of a bifidobacterium animalis subsp. Lactis BLa36 bacterial strain, a bifidobacterium longum BL21 bacterial strain, a bifidobacterium adolescentis BAC30 bacterial strain, a lactobacillus plantarum Lp90 bacterial strain, a lactobacillus casei LC89 bacterial strain, a bifidobacterium breve BBr60 bacterial strain and a pediococcus acidilactici CCFM7902 bacterial strain. After the rhizoma polygonati component and the probiotic component are combined for use, the rhizoma polygonati component and the probiotic component have potential synergistic effects in the aspects of improving the intestinal flora structure, regulating the intestinal environment, delaying senescence, reducing inflammation-related symptoms and the like. Moreover, further, various probiotic strains are compounded and combined for use, so that the capability of a related compound preparation in the aspect of delaying various symptoms of senescence can also be improved in a combined manner.

The invention belongs to the technical field of biology, and particularly relates to animal bifidobacterium subsp. Lactis FMBL B24304AHDM and application thereof.The animal bifidobacterium subsp. Lactis FMBL B24304AHDM is preserved in the China Center for Type Culture Collection on November 18, 2024, the preservation number is CCTCC NO: M 20242505, and the animal bifidobacterium subsp. Lactis FMBL B24304AHDM has the good inhibition capacity on pathogenic bacteria and has the high scavenging capacity on DPPH and ABTS free radicals; the compound has the effect of inhibiting the activity of alpha-glucosidase, alpha-amylase and dipeptidyl peptidase IV, and the oral glucose tolerance and insulin tolerance of T2DM mice can be remarkably reduced; the composition of intestinal microbiome is obviously improved, the abundance and variety of effective microbial communities in the intestinal tract are improved, and the relative abundance of pathogenic bacteria is reduced, so that the disorder of short-chain fatty acids of T2DM mice is improved, and the application prospect is wide.

The invention relates to bifidobacterium animalis subsp. Lactis CBTL010 and application thereof in products for improving intestinal flora and relieving depression and anxiety, and belongs to the technical field of microorganisms. The bifidobacterium animalis subsp. Lactis CBTL010 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation time is March 20, 2025, the preservation number is CGMCC NO.33906, and the bifidobacterium animalis subsp. Lactis CBTL010 has the effects of improving intestinal flora and relieving depression and anxiety.

The invention relates to application of bifidobacterium animalis subsp. Lactis BLa80 in preparation of a preparation for relieving depression or anxiety. The bifidobacterium animalis subsp. Lactis BLa80 is a strain of the bifidobacterium animalis subsp. Lactis BLa80 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.22547, and the strain of the bifidobacterium animalis subsp. Lactis BLa80 is a strain of the bifidobacterium animalis subsp. Lactis BLa80 with the preservation number of CGMCC No.22547. The invention develops a brand new application of the bifidobacterium animalis subsp. Lactis BLa80 strain, namely, the bifidobacterium animalis subsp. Lactis BLa80 strain is used for relieving depression or anxiety symptoms, specifically, the bifidobacterium animalis subsp. Lactis BLa80 strain can stimulate RIN14B cells to secrete 5-HT, can relieve depression and anxiety-like behaviors of mice suffering from depression and anxiety, can relieve hyperfunction of hypothalamic-pituitary-adrenal axis (HPA axis), and can relieve depression and anxiety-like behaviors of mice suffering from depression and anxiety. The inflammatory response of mice with depression and anxiety is relieved, the expression level of brain-derived neurotrophic factors in hippocampus of the mice with depression and anxiety is improved, the abundance of intestinal beneficial flora of the mice with depression and anxiety is improved, and the diversity of intestinal flora is increased.

The present invention belongs to the technical field of extracting effective pharmaceutical ingredients, and particularly relates to a composition containing citrus polyphenols and citrus powder for burning fat and losing weight, and a preparation method and application thereof. The composition comprises a spray-dried powder prepared from citrus fruit filtrate, Flammulina velutipes fiber, soy protein isolate, aronia berry extract, and black tea extract, and a compound probiotic, wherein the compound probiotic comprises Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus rhamnosus, Bifidobacterium lactis, and Lactobacillus casei. The present invention adopts compound spraying of Flammulina velutipes fiber, soy protein isolate, aronia berry extract, black tea extract, and citrus fruit filtrate to improve the stability of total polyphenols and Vc in citrus fruits. The obtained citrus powder is further mixed with a compound probiotic to prepare a composition with pharmacologically active ingredients, which can effectively burn fat and lose weight and can be applied to weight loss drugs.

The invention discloses a preparation process of metabiotics and functional application of the metabiotics for relieving constipation, and relates to the technical field of microorganisms. The invention provides a preparation method of a bifidobacterium animalis subsp. Lactis LIHUO 01-containing metagen, which comprises the following steps: separately inoculating bifidobacterium animalis subsp. Lactis LIHUO 01 or compounding with probiotics to inoculate in a fermentation culture medium for culturing to obtain a fermentation bacteria solution, and carrying out thermal inactivation to obtain the bifidobacterium animalis subsp. Lactis LIHUO 01-containing metagen. The fermentation medium comprises skimmed milk, soybean meal and water, the mass ratio of the skimmed milk to the soybean meal to the water is (5-30): (1-25): (78-90), and the prepared bifidobacterium animalis subsp. Lactis LISUO 01 metabolite can significantly improve the content of tryptophan metabolites, can effectively relieve constipation and has a wide application prospect.

The application discloses an animal bifidobacterium producing bile salt hydrolase and application thereof in neonatal jaundice, and belongs to the technical field of microorganisms. The animal bifidobacterium lactis WXM screened by the application has the effect of relieving neonatal jaundice, can significantly improve weight loss of a jaundice individual in an early life stage, improve abnormal increase of a bilirubin level in serum, improve liver damage, improve the level of an enzyme related to liver function, the expression level of a related inflammatory factor in the liver and the expression level of an enzyme UGT1A1 related to bilirubin metabolism, and has the effect of relieving neonatal jaundice. The strain of the application has high safety and has wide application value in the fields of food, functional food, health products, medicine and the like.

The invention belongs to the technical field of microorganisms, and discloses a bifidobacterium animalis subsp. Lactis XB02 strain capable of inhibiting pathogenic bacteria and improving inflammation, the preservation number of the bifidobacterium animalis subsp. Lactis XB02 strain is CGMCC (China General Microbiological Culture Collection Center) No.34942, and the preservation date is June 18, 2025. Meanwhile, the probiotic composition adopting the bacterial strain XB02 also comprises a lactobacillus rhamnosus XB01 bacterial strain. The XB02 strain disclosed by the invention has excellent bacteriostatic activity, especially for vibrio parahaemolyticus and gardneria; the atopic dermatitis symptom can be obviously improved; the intestinal mucosa permeability is reduced, and the intestinal barrier function is enhanced; and when the strain is combined with the XB01 strain for use, a synergistic sleep promoting effect is shown. The invention further provides a probiotic composition containing the strain, a preparation and application of the probiotic composition and the preparation in food, medicine or health care products.

The invention relates to an application of plant lactobacillus Hi188 in promotion of bone health. The invention provides the application of the plant lactobacillus Hi188 or the afterbiogen thereof or the composition thereof in increasing the bone mineral density, increasing the bone mineral density, promoting the skeletal development, increasing the bone mineral content and / or promoting the tibia growth. Or preparing food for increasing bone mineral density, increasing bone mineral density, promoting skeletal development, increasing bone mineral content and / or promoting tibia growth; wherein the composition comprises: (A) Phytobacterium plantarum Hi188 or a postbiotic thereof, and (B) Bifidobacterium lactis Ca360 or a postbiotic thereof.

This paper discusses a strain of Bifidobacterium animalis subsp. lactis B7 and its composition and applications, belonging to the field of microbial technology. The specific strain is Bifidobacterium animalis subsp. lactis B7. Bifidobacterium animalis subsp. lactis Bifidobacterium lactis subspecies B7 was deposited at the China Center for Type Culture Collection on April 19, 2024, with accession number CCTCC NO: M2024734. This invention also discloses the application of the B7 fermentation composition in the preparation of drugs for the prevention and treatment of ulcerative colitis, constipation, and constipation-predominant ulcerative colitis. This animal bifidobacterium lactis subspecies B7 produces high levels of short-chain fatty acids and indolepropionic acid, utilizes sulforaphane to generate sulforaphane, increases intestinal peristalsis, effectively alleviates the disease activity index (DAI) and weight loss caused by ulcerative colitis or inflammatory bowel disease, significantly reduces colonic damage in mice, protects the mucosal layer, has anti-inflammatory effects, inhibits pathogens, and improves intestinal barrier function.

The invention belongs to the technical field of pet food, and particularly relates to compound papain containing probiotics and application of the compound papain in pet digestion aiding products. The compound papain is prepared from active ingredients and auxiliary ingredients, wherein the active ingredients are mixed with the auxiliary ingredients; the active component is prepared from papain, bacillus subtilis protease and probiotics; the probiotics are prepared from lactobacillus acidophilus and bifidobacterium lactis. According to the compound papain disclosed by the invention, a double-enzyme design of papain and bacillus subtilis protease is adopted, so that the digestibility is remarkably improved, the digestion function of pets is favorably improved, nutrient substances in pet food are favorably absorbed, and the incidence rate of digestive system diseases is further favorably reduced. Besides, the double-probiotic design of lactobacillus acidophilus and bifidobacterium lactis is added on the basis of the double-enzyme design, so that the digestibility of the pet food can be further improved, the defect of adopting single protease or only depending on protease is overcome, and the method has a relatively good application prospect.

The invention discloses a probiotic strain Bifidobacterium animalis subsp. Lactiss S8 of a high-yield biological membrane, the preservation number is GDMCC NO.66518, the characteristics of the stable high-yield biological membrane are obtained through directional screening and adaptive evolution, and the yield of the biological membrane is three times higher than that of a positive control. The extracellular polymeric substance (EPS) of the strain can significantly enhance the tolerance of the strain to severe environments such as gastric acid, cholate and the like, and improve the intestinal colonization ability. Experiments prove that the strain remarkably reduces two liver function indexes, namely ALT and AST, in an animal model, and shows that the strain has a certain effect of improving liver injury.

The present invention provides a composition containing oligofructose and probiotics and its application. The probiotics in the composition containing oligofructose and probiotics of the present invention are animal Bifidobacterium BB12, Bifidobacterium lactis HN019 and Bifidobacterium longum infantis subspecies GB-1496. The present invention also provides the application of the above composition in promoting the proliferation of Bifidobacterium longum infantis subspecies GB-1496. The present invention has found that using FOS as a carbon source and compounding Bifidobacterium animalis BB12, Bifidobacterium lactis HN019 and Bifidobacterium longum infantis subspecies GB-1496 can significantly promote the proliferation of Bifidobacterium infantis, and the number of proliferation is significantly higher than the single combination of FOS and animal Bifidobacterium BB12, Bifidobacterium lactis HN019 and Bifidobacterium longum infantis subspecies GB-1496.

The invention discloses a composition and application thereof in preparation of a product for supplementing butyric acid, and the composition comprises the following components in parts by weight: 2-10 parts of lactobacillus acidophilus, 2-10 parts of bifidobacterium lactis, 20-40 parts of barley seedlings, 20-40 parts of broccoli, 1-5 parts of Chinese yam and 2-10 parts of hawthorn. The composition provided by the invention contains fruits, vegetables and probiotics in a reasonable ratio, can provide high-quality prebiotics for growth and metabolism of intestinal microorganisms, regulate metabolism of intestinal short-chain fatty acids, improve the total content of the intestinal short-chain fatty acids, and also remarkably promote the production of butyric acid, so that the mass ratio of butyric acid to propionic acid is greater than or equal to 4: 1, and the content of the butyric acid is greater than or equal to 1. The intestinal function of a human body can be improved, and the intestinal health is maintained.

The invention relates to the technical field of microbial fermentation, and discloses a moisturizing and soothing bifidobacterium lactis SF-B-20 fermentation product as well as a preparation method and application thereof, and the preservation number of bifidobacterium lactis SF-B-20 is CGMCC (China General Microbiological Culture Collection Center) No.20924. The moisturizing and soothing bifidobacterium lactis SF-B-20 fermentation product is prepared by fermenting a fermented substrate with bifidobacterium lactis SF-B-20, and the fermented substrate comprises a Chinese herbal medicine extract and a fed-batch culture medium; chinese herbal medicine raw materials for preparing the Chinese herbal medicine extract comprise the following components: silver birch juice, radix ampelopsis, astragalus membranaceus, aloe, purslane, liquorice, chamomile and radix sophorae flavescentis, the fed-batch culture medium comprises the following components: glucose, peptone, yeast extract powder and tremella polysaccharide, and the moisturizing and soothing bifidobacterium lactis SF-B-20 yeast has moisturizing and soothing effects and is safe and non-irritating.

The invention discloses bifidobacterium animalis subsp. Lactis CCMXJ2003 as well as a composition and application thereof, and belongs to the technical field of microbial preparations. In order to screen a specific probiotic strain which can form efficient synergy with 2 '-fucosyllactose and has good viability and an immunoregulation function, and construct a precise micro-ecological intervention scheme aiming at atopic dermatitis immunopathology key links, the invention provides a microecological intervention method for the atopic dermatitis immunopathology key links. The invention provides the bifidobacterium animalis subsp. Lactis CCMXJ2003 capable of efficiently utilizing the 2 '-fucosyllactose, and an in-vivo experiment proves that the composition of the 2'-fucosyllactose and the bifidobacterium animalis subsp. Lactis CCMXJ2003 shows an obvious enhancement effect in the aspect of relieving the specific dermatitis; the compound has a wide application prospect in prevention and / or treatment of atopic dermatitis.

The application provides an animal Bifidobacterium lactis HNU329 with the ability of reducing uric acid and an application thereof, the animal Bifidobacterium lactis HNU329 has been preserved in the Guangdong Microbial Culture Collection Center (GDMCC), the preservation address is the 5th floor of the 59th building of the courtyard, No. 100, Jiefang Road, Guangzhou, the preservation date is April 22, 2024, the preservation number is GDMCC No: 64546, and the classification and naming are Bifidobacterium animalis subsp. Lactis. The strain has good degradation abilities of nucleosides and purines in vitro, also shows good uric acid reducing ability and anti-inflammatory ability in animal model evaluation, and can regulate the intestinal flora of hyperuricemia mice and improve the symptoms of hyperuricemia. The strain is non-toxic and has no side effects, is safe, and has a wide application prospect.